Clinical outcome and potential benefits of post-progression immunotherapy for patients with metastatic NSCLC with primary resistance to ipilumumab and nivolumab in the LONESTAR phase III study.

Mehmet  Altan

Consulting or Advisory Role - AstraZeneca; BMS; GlaxoSmithKline

Speakers' Bureau - Nektar

Research Funding - Adaptimmune (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Jounce Therapeutics (Inst); Lilly (Inst); Merck (Inst); Nektar (Inst); Novartis (Inst); Shattuck Labs (Inst)

Travel, Accommodations, Expenses - Nektar

Dawen  Sui

No Relationships to Disclose

Saumil  Gandhi

No Relationships to Disclose

Stephen  Swisher

Honoraria - Armada Health Care (I); Merck (I)

Research Funding - CairnSurgical (I); Lilly (I); Lumicell (I); OncoNano Inc (I)

Travel, Accommodations, Expenses - Peter MacCallum Cancer Center

Natalie I  Vokes

Honoraria - Sanofi

Consulting or Advisory Role - Sanofi/Regeneron

Mara  Antonoff

No Relationships to Disclose

Jianjun  Zhang

Honoraria - CancerNet; Geneplus; Geneplus; innovent biologics; Innovent Biologics; Innovent Biologics; Origimed; Roche; Sino-USA Biomedical Platform; Zhejiang Cancer Hospital; Zhejiang Cancer Hospital

Consulting or Advisory Role - AstraZeneca; AstraZeneca; AstraZeneca; Capital Medical University; Geneplus; Johnson & Johnson/Janssen; Novartis

Research Funding - Merck; Novartis

Travel, Accommodations, Expenses - innovent biologics; Zhejiang Cancer Hospital

George R.  Blumenschein

Employment - Janssen (I); johnon & Johnson (I)

Stock and Other Ownership Interests  - Virogin Biotech

Consulting or Advisory Role - Abbvie; Adicet Bio; Amgen; ARIAD; AstraZeneca; Bayer; Bristol-Myers Squibb; Celgene; Clovis Oncology; Daiichi Sankyo, INC; Genentech; Gilead Sciences; Instil Bio; Janssen Oncology; Johnson & Johnson (I); Lilly; Maverick Therapeutics; MedImmune; Merck; Novartis; Novartis; Roche; Tyme; Virogin Biotech; Xcovery

Research Funding - Adaptimmune; AstraZeneca; Bayer; BeiGene; Bristol-Myers Squibb; Celgene; Daiichi Sankyo INC; Exelixis; Genentech; GlaxoSmithKline; Immatics; Immunocore; Incyte; Kite, a Gilead company; Macrogenics; MedImmune; Merck; Novartis; Regeneron; Repertoire Immune Medicines; Roche; Tmunity Therapeutics, Inc.; Torque; Verastem; Xcovery

Tina  Cascone

Honoraria - Bristol-Myers Squibb; Brystol-Myers Squibb; Medscape; Roche; Society for Immunotherapy of Cancer

Consulting or Advisory Role - Arrowhead Pharmaceuticals; AstraZeneca; Bristol Myers Squibb; EMD Serono; Genentech; MedImmune; Merck

Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); MedImmune (Inst)

Travel, Accommodations, Expenses - Parker Institute for Cancer Immunotherapy

Yasir Y  Elamin

Consulting or Advisory Role - AstraZeneca; Lilly; Sanofi; Takeda; Turning Point Therapeutics

Research Funding - AstraZeneca; Blueprint Medicines; Elevation Oncology; Forward; Lilly; Precision Therapeutics; Spectrum Pharmaceuticals; Takeda; Turning Point Therapeutics; Xcovery

Travel, Accommodations, Expenses - Lilly

Carl Michael  Gay

Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Jazz Pharmaceuticals

Speakers' Bureau - AstraZeneca; BeiGene

Research Funding - AstraZeneca; GlaxoSmithKline (Inst); Merck (Inst)

Don Lynn  Gibbons

Stock and Other Ownership Interests  - Exact Sciences; Nektar

Consulting or Advisory Role - GlaxoSmithKline; Janssen Research & Development; Lilly; Menarini; Mitobridge; Napa Therapeutics; Ribon Therapeutics; Sanofi

Research Funding - AstraZeneca; Boehringer Ingelheim (Inst); Janssen Research & Development; Mirati Therapeutics (Inst); Mitobridge; NGM Biopharmaceuticals; Ribon Therapeutics; Takeda

Travel, Accommodations, Expenses - AstraZeneca/MedImmune; BerGenBio; Takeda

Xiuning  Le

Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo/Lilly; EMD Serono; Lilly; Spectrum Pharmaceuticals

Research Funding - Boehringer Ingelheim (Inst); Lilly (Inst)

Marcelo Vailati  Negrao

Consulting or Advisory Role - Merck; Mirati Therapeutics

Research Funding - Alaunos Therapeutics; AstraZeneca; Checkmate Pharmaceuticals; Genentech; Mirati Therapeutics; Novartis; Pfizer; ZIOPHARM Oncology

Other Relationship - Apothecom; Ashfield Healthcare; ZIOPHARM Oncology

Ferdinandos  Skoulidis

Stock and Other Ownership Interests  - BioNTech; Moderna Therapeutics

Honoraria - ESMO; McGill Universite de Montreal; RV Mais

Consulting or Advisory Role - Amgen; BeiGene; Calithera Biosciences; Intellisphere; Medscape; Navire; Tango Therapeutics

Research Funding - AIMM Therapeutics (I); Amgen (Inst); Boehringer Ingelheim (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst)

Anne S.  Tsao

Consulting or Advisory Role - ARIAD; AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; EMD Serono; Epizyme; Genentech/Roche; HERON; Lilly; Novartis; Takeda

Research Funding - Boehringer Ingelheim; Bristol-Myers Squibb; Bristol-Myers Squibb; EMD Serono; Genentech/Roche; Merck; Millennium; Polaris; Seagen; Seagen; Takeda

Patents, Royalties, Other Intellectual Property - UptoDate

Janet Chen  Tu

No Relationships to Disclose

Amy R.  Spelman

No Relationships to Disclose

J. Jack  Lee

Honoraria - AstraZeneca; AstraZeneca

John  Heymach

Stock and Other Ownership Interests  - Bio-Tree; Cardinal Spine

Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; BrightPath Biotheraputics; Bristol-Myers Squibb; Catalyst Biotech; EMD Serono; Foundation medicine; Genentech/Roche; GlaxoSmithKline; Guardant Health; Hengrui Pharmaceutical; Janssen; Kairos Ventures; Leads Biolabs; Lilly; Mirati Therapeutics; Nexus Health Systems; Novartis; Pneuma Respiratory; Roche; Sanofi/Aventis; Spectrum Pharmaceuticals; Takeda

Research Funding - AstraZeneca (Inst); GlaxoSmithKline; Spectrum Pharmaceuticals

Patents, Royalties, Other Intellectual Property - Licensing agreement between Spectrum and MD Anderson (including myself) regarding intellectual property for treatment of EGFR and HER2 exon 20 mutations